Saluda Medical Secures European Regulator Approval for EVA Sensing Technology Product

MT Newswires Live12-22

Saluda Medical (ASX:SLD) said its next-generation EVA Sensing Technology product has now received CE certification for commercialization in Europe, with recognition of this approval in Australia, according to a Monday Australian bourse filing.

This follows the US Food and Drug Administration approval of EVA in December 2024, the filing added.

The company said its EVA Sensing Technology automates manual programming steps and objectively scans and analyzes a patient's spinal cord to deliver therapy with optimized precision.

"This approval is in line with our expectations and builds on the successful commercialisation we've seen in the US, this expansion allows us to bring a proven technology enhancement to more markets," said Chief Executive Barry Regan.

The company added that a limited commercial release in Europe and Australia will begin in the first calendar quarter of 2026, followed by a full commercial release later in the year, and the timing of this approval and launch is in line with the company's internal expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593710150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 14:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593710150","market":"fut","top_or_hot":-1,"title":"Saluda Medical Secures European Regulator Approval for EVA Sensing Technology Product","media":"MT Newswires Live","content":"<html><body><p> Saluda Medical (ASX:SLD) said its next-generation EVA Sensing Technology product has now received CE certification for commercialization in Europe, with recognition of this approval in Australia, according to a Monday Australian bourse filing.</p><p>This follows the US Food and Drug Administration approval of EVA in December 2024, the filing added.</p><p>The company said its EVA Sensing Technology automates manual programming steps and objectively scans and analyzes a patient's spinal cord to deliver therapy with optimized precision.</p><p>\"This approval is in line with our expectations and builds on the successful commercialisation we've seen in the US, this expansion allows us to bring a proven technology enhancement to more markets,\" said Chief Executive Barry Regan.</p><p>The company added that a limited commercial release in Europe and Australia will begin in the first calendar quarter of 2026, followed by a full commercial release later in the year, and the timing of this approval and launch is in line with the company's internal expectations.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Saluda Medical Secures European Regulator Approval for EVA Sensing Technology Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSaluda Medical Secures European Regulator Approval for EVA Sensing Technology Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-22 14:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Saluda Medical (ASX:SLD) said its next-generation EVA Sensing Technology product has now received CE certification for commercialization in Europe, with recognition of this approval in Australia, according to a Monday Australian bourse filing.</p><p>This follows the US Food and Drug Administration approval of EVA in December 2024, the filing added.</p><p>The company said its EVA Sensing Technology automates manual programming steps and objectively scans and analyzes a patient's spinal cord to deliver therapy with optimized precision.</p><p>\"This approval is in line with our expectations and builds on the successful commercialisation we've seen in the US, this expansion allows us to bring a proven technology enhancement to more markets,\" said Chief Executive Barry Regan.</p><p>The company added that a limited commercial release in Europe and Australia will begin in the first calendar quarter of 2026, followed by a full commercial release later in the year, and the timing of this approval and launch is in line with the company's internal expectations.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593710150","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593710150","pubTimestamp":1766386246,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Saluda Medical  said its next-generation EVA Sensing Technology product has now received CE certification for commercialization in Europe, with recognition of this approval in Australia, according to a Monday Australian bourse filing.This follows the US Food and Drug Administration approval of EVA in December 2024, the filing added.The company said its EVA Sensing Technology automates manual programming steps and objectively scans and analyzes a patient's spinal cord to deliver therapy with optimized precision.\"This approval is in line with our expectations and builds on the successful commercialisation we've seen in the US, this expansion allows us to bring a proven technology enhancement to more markets,\" said Chief Executive Barry Regan.The company added that a limited commercial release in Europe and Australia will begin in the first calendar quarter of 2026, followed by a full commercial release later in the year, and the timing of this approval and launch is in line with the comp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","BK4156":"煤与消费用燃料","EVA":"Enviva Partners, LP","SLD.AU":"Saluda Medical Inc"},"translate_title":"Saluda Medical EVA传感技术产品获得欧洲监管机构批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVA":1.5,"SLD.AU":1},"content_text":"Saluda Medical (ASX:SLD) said its next-generation EVA Sensing Technology product has now received CE certification for commercialization in Europe, with recognition of this approval in Australia, according to a Monday Australian bourse filing.This follows the US Food and Drug Administration approval of EVA in December 2024, the filing added.The company said its EVA Sensing Technology automates manual programming steps and objectively scans and analyzes a patient's spinal cord to deliver therapy with optimized precision.\"This approval is in line with our expectations and builds on the successful commercialisation we've seen in the US, this expansion allows us to bring a proven technology enhancement to more markets,\" said Chief Executive Barry Regan.The company added that a limited commercial release in Europe and Australia will begin in the first calendar quarter of 2026, followed by a full commercial release later in the year, and the timing of this approval and launch is in line with the company's internal expectations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593710150","isCrawlerRequest":true}